Please login to the form below

Not currently logged in
Email:
Password:

pneumococcal disease

This page shows the latest pneumococcal disease news and features for those working in and with pharma, biotech and healthcare.

Pfizer’s Prevnar-13 successor takes aim at Merck rival

Pfizer’s Prevnar-13 successor takes aim at Merck rival

Pfizer. “There continues to be a global health need to protect against the potentially devastating effects of invasive pneumococcal disease and pneumonia caused by additional serotypes, and we are dedicated to ... continue to build on our expertise in

Latest news

  • CHMP thumbs up for Novo's obesity drug Saxenda CHMP thumbs up for Novo's obesity drug Saxenda

    prevention of pneumonia caused by the 13 pneumococcal serotypes in the vaccine in adults 18 years and older. ... The vaccine is currently approved in Europe for the prevention of invasive pneumococcal disease in the same population.

  • US panel backs pneumococcal vaccines for seniors US panel backs pneumococcal vaccines for seniors

    Meanwhile, Merck said it was pleased that Pneumovax 23 would continue to play an integral role in helping to prevent pneumococcal disease in adults who are at increased risk. ... Pneumococcal disease is still a significant burden and millions of adults

  • Pfizer closes on $1bn label expansion for Prevenar Pfizer closes on $1bn label expansion for Prevenar

    Pfizer closes on $1bn label expansion for Prevenar. EMA begins review of the pneumococcal vaccine. ... The vaccine is already approved in Europe for preventing invasive pneumococcal disease in adults, a less common but more serious infection

  • Pfizer acquires Baxter Men C and encephalitis vaccines for $635m Pfizer acquires Baxter Men C and encephalitis vaccines for $635m

    Susan Silbermann, president of Pfizer Vaccines, said: “ For over a decade Pfizer has been the global leader in pneumococcal disease prevention. ... The company's deal with Pfizer did not include either its influenza vaccine development programme, nor

  • GSK and Pfizer extend vaccine access programme GSK and Pfizer extend vaccine access programme

    GSK and Pfizer extend vaccine access programme. Pharma companies lower price of pneumococcal vaccines for developing nations. ... GSK will provide Synflorix at a cost of $3.40 per dose up to 2024, with the company claiming it will help protect an

More from news
Approximately 1 fully matching, plus 28 partially matching documents found.

Latest Intelligence

  • A tailored approach to the BRIC markets A tailored approach to the BRIC markets

    In 2009, GSK signed a 1.5bn deal with the Brazilian government to provide Syflorix, its vaccine for paediatric pneumococcal disease, at around a third of the price it charged in

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...

Infographics